Amani Therapeutics has filed a notice of an exempt offering of securities to raise $60 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Amani Therapeutics is raising up to $59,999,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Amani Therapeutics
Amani Therapeutics is a biotechnology company focused on developing innovative, safer, and more effective treatments for people living with serious psychiatric illnesses. Its mission is to advance psychiatric therapies faster while restoring hope and stability so patients can lead fuller lives. The companys lead program, AM-01, is a fixed-dose combination of clozapine and a Phase 3-ready new chemical entity licensed worldwide from AstraZeneca. Amani believes AM-01 could preserve clozapines unmatched effectiveness for treatment-resistant schizophrenia while addressing severe neutropenia and the burdensome blood monitoring that limit clozapines use. Clozapine is the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and reduce suicide risk in people with schizophrenia and schizoaffective disorder, yet it remains significantly underused because of safety concerns and monitoring requirements. In March 2026, Amani Therapeutics announced that it had closed a $25 million Series A financing to advance AM-01 as a potential best-in-class therapy for serious neuropsychiatric disorders.

To learn more, visit https://amanitx.com/
LinkedIn: https://www.linkedin.com/company/amani-therapeutics/

Contact:
Robert Swoboda, Chief Operating Officer
https://www.linkedin.com/in/rob-swoboda/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.